Journal Article > CommentaryFull Text
Nature. 2022 February 9; Volume 602 (Issue 7896); 207-210.; DOI:10.1038/d41586-022-00324-y
Swaminathan S, Pecoul B, Abdullah H, Christou C, Gray G, et al.
Nature. 2022 February 9; Volume 602 (Issue 7896); 207-210.; DOI:10.1038/d41586-022-00324-y
Other > Journal Blog
BMJ. 2019 July 11
Torreele E
BMJ. 2019 July 11
Journal Article > EditorialFull Text
Bull World Health Organ. 2019 May 1; Volume 97 (Issue 5); 311-311A.; DOI:10.2471/BLT.19.234468
Tatay M, Torreele E
Bull World Health Organ. 2019 May 1; Volume 97 (Issue 5); 311-311A.; DOI:10.2471/BLT.19.234468
Journal Article > Short ReportFull Text
PLOS Med. 2017 April 18; Volume 14 (Issue 4); e1002276.; DOI:10.1371/journal.pmed.1002276
Balasegaram M, Kolb P, McKew J, Menon J, Olliaro PL, et al.
PLOS Med. 2017 April 18; Volume 14 (Issue 4); e1002276.; DOI:10.1371/journal.pmed.1002276
Journal Article > CommentaryFull Text
BMJ Glob Health. 2021 February 1; Volume 6 (Issue 2); e005306.; DOI:10.1136/bmjgh-2021-005306
Boum Y II, Ouattara AK, Torreele E, Okonta C
BMJ Glob Health. 2021 February 1; Volume 6 (Issue 2); e005306.; DOI:10.1136/bmjgh-2021-005306
SUMMARY POINTS
• Limited access to vaccines by African nations as Africa has been side-lined in the race to secure vaccines for COVID-19.
•. Uniform thinking and planning overlook distinct country realities that may imply different COVID-19 responses, including vaccination strategies, and that local stakeholders and communities have a central role in designing and implementing successful public health interventions.
•. The distribution of COVID-19 vaccines should be part of an integrated and broader strategy, both to curb COVID-19 and also to improve life and well-being of the target community.
•. The backdrop of Africa in the COVID-19 vaccine race highlights the urgency for Africans to invest in research to ensure that strategies are adapted to the Africa context and not just imported as the COVID-19 vaccine will be.
• Limited access to vaccines by African nations as Africa has been side-lined in the race to secure vaccines for COVID-19.
•. Uniform thinking and planning overlook distinct country realities that may imply different COVID-19 responses, including vaccination strategies, and that local stakeholders and communities have a central role in designing and implementing successful public health interventions.
•. The distribution of COVID-19 vaccines should be part of an integrated and broader strategy, both to curb COVID-19 and also to improve life and well-being of the target community.
•. The backdrop of Africa in the COVID-19 vaccine race highlights the urgency for Africans to invest in research to ensure that strategies are adapted to the Africa context and not just imported as the COVID-19 vaccine will be.
Journal Article > EditorialFull Text
Bull World Health Organ. 2017 May 1; Volume 95 (Issue 5); DOI:10.2471/BLT.17.194837
Brigden G, Castro JL, Ditiu L, Gray G, Hanna D, et al.
Bull World Health Organ. 2017 May 1; Volume 95 (Issue 5); DOI:10.2471/BLT.17.194837
Journal Article > LetterFull Text
PLOS Glob Public Health. 2024 October 17; Volume 4 (Issue 10); e0003714.; DOI:10.1371/journal.pgph.0003714
McNab C, Torreele E, Alakija A, Aluso A, Cárdenas M, et al.
PLOS Glob Public Health. 2024 October 17; Volume 4 (Issue 10); e0003714.; DOI:10.1371/journal.pgph.0003714
Journal Article > ResearchFull Text
Lancet. 2006 May 13; Volume 367 (Issue 9522); DOI:10.1016/S0140-6736(06)68672-8
Chirac P, Torreele E
Lancet. 2006 May 13; Volume 367 (Issue 9522); DOI:10.1016/S0140-6736(06)68672-8
Journal Article > LetterFull Text
JAMA. 2001 December 19; Volume 286 (Issue 23); 2943-2944.; DOI:10.1001/jama.286.23.2943
Ford NP, Torreele E
JAMA. 2001 December 19; Volume 286 (Issue 23); 2943-2944.; DOI:10.1001/jama.286.23.2943
To the Editor: We agree with Mr Folkers and Dr Fauci that the success of acquired immunodeficiency syndrome research over the last 2 decades shows what can be achieved if enough financial and human resources are provided.1 There was serious commitment from Western governments as well as major investments from the pharmaceutical industry that anticipated a hugely profitable market in developed countries.....
Journal Article > CommentaryFull Text
Lancet Infect Dis. 2023 January 19; Online ahead of print; DOI:10.1016/S1473-3099(22)00810-6
Torreele E, Boum Y, Adjaho I, Alé FGB, Issoufou SH, et al.
Lancet Infect Dis. 2023 January 19; Online ahead of print; DOI:10.1016/S1473-3099(22)00810-6
Three years since proving effective for Ebola virus disease in a clinical trial, two breakthrough treatments are registered and stockpiled in the USA but still not registered and generally available in the countries most affected by this deadly infection of epidemic potential. Analysing the reasons for this, we see a fragmentation of the research and development value chain, with different stakeholders taking on different steps of the research and development process, without the public health-focused leadership needed to ensure the end goal of equitable access in countries where Ebola virus disease is prevalent. Current financial incentives for companies to overcome market failures and engage in epidemic-prone diseases are geared towards registration and stockpiling in the USA, without responsibility to provide access where and when needed. Ebola virus disease is the case in point, but not unique—a situation seen again for mpox and likely to occur again for other epidemics primarily affecting disempowered communities. Stronger leadership in African countries will help drive drug development efforts for diseases that primarily affect their communities, and ensure all partners align with and commit to an end-to-end approach to pharmaceutical development and manufacturing that puts equitable access when and where needed at its core.